Loading...
XSHE
002332
Market cap1.19bUSD
Jul 10, Last price  
8.25CNY
1D
0.86%
1Q
-8.44%
Jan 2017
-3.85%
IPO
0.73%
Name

Zhejiang Xianju Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002332 chart
P/E
18.15
P/S
2.17
EPS
0.45
Div Yield, %
4.89%
Shrs. gr., 5y
Rev. gr., 5y
-1.33%
Revenues
3.76b
-6.04%
765,330,681966,789,3371,133,516,5221,276,721,0341,500,980,9331,689,209,5981,992,191,5442,315,040,5642,470,533,0182,480,246,1532,503,730,3442,852,555,2623,621,754,7123,708,545,5304,018,872,7724,357,346,3414,379,825,6954,123,418,5824,000,693,1473,758,969,165
Net income
450m
+13.21%
49,529,72464,636,46165,037,69988,841,792120,165,635132,869,614120,557,25960,591,47356,695,721106,551,044146,186,893206,630,131301,362,973410,368,591504,509,432619,325,647749,411,383563,083,497397,179,000449,640,395
CFO
247m
-37.92%
53,052,17996,534,59036,030,822104,678,023155,292,369147,627,79833,427,87163,461,725141,638,736199,607,086155,905,554167,466,085193,266,995519,805,113789,233,376676,151,765609,284,602595,482,358398,655,375247,478,004
Dividend
Oct 22, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Xianju Pharmaceutical Co.,Ltd. is a global enterprise specializing in the production and distribution of steroidal and hormonal pharmaceutical products. Its offerings span active pharmaceutical ingredients (APIs), specifically steroid-based medications and both male and female hormones, alongside various chemical intermediates. The company also provides a comprehensive selection of finished dosage forms, including tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-for-injection preparations. Established in 1972, Zhejiang Xianju Pharmaceutical Co.,Ltd. operates from its headquarters in Xianju, China.
IPO date
Jan 12, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT